Larimar Therapeutics, Inc. announced a director or officer change
SEC 8-KRead source ↗
Larimar Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Stock price today
Loading chart…
Third-party market data · may be delayed
Model estimate per share
~$1.2
Forward price-to-sales vs peers
Base case. Range ~$1.2–$4.8. Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative.
Price vs value
No Buy/Hold/Sell rating is issued: limited reported history: available models are shown without a Buy/Hold/Sell rating.
Larimar Therapeutics, Inc. valuation: adjust assumptions and compare models →
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders4 buying, 0 selling8 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
- Funds100 adding, 69 cuttingOf 41 active managers that changed their stake, 24 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 20% in the quarter to 2026-06-30, the 2nd beat in the last four quarters.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Larimar Therapeutics, Inc.'s latest figures clears our strength thresholds.
Things to watch
- Volatile shares. Over the past year the shares showed annualised volatility of 100% and a beta of 1.6 against the S&P 500.
- Heavily shorted. 21.8% of the shares available to trade are sold short (8.7 days of average volume to cover).
- Missing expectations. Earnings per share fell short of the consensus estimate in 2 of the last four quarters.
Latest results
- Earnings per share
- -$0.30 against an average estimate of -$0.38: beat by 20.2%
- Share reaction
- +3.0% in the first session after the results on August 4, 2026, against +1.6% for the S&P 500
- Next report
- November 5, 2026; average EPS estimate -$0.35
Price chart
- 1 day-4.0%
- 1 week+5.8%
- 1 month-19.9%
- This year-37.8%
- 1 year-39.1%
- 5 years-82.1%
- S&P 500 this year+11.2%
Loading chart…
Third-party market data · may be delayed
At a glance
Earnings
- Last results
- August 4, 2026
News & updates
Company announcements, filed results and changes that matter to shareholders.
- Leadership
- Results
Larimar Therapeutics, Inc. reported results; disclosed a material event
SEC 8-KRead source ↗
Valuation models
We value Larimar Therapeutics, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.2%: the 10-year Treasury yield (4.9%) plus a beta of 1.17 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. | ~$1.2 ~$1.3–$4.8 | Included, half weight |
| Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | ~$1.2 ~$1.2–$4.8 | 1 model |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Larimar Therapeutics, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Next results: November 5, 2026, before the open. Analysts expect revenue of $0 and EPS of −$0.35 (range −$0.37 to −$0.31) for the quarter.
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$1.35 | +41% | — | 0% |
| Next | −$1.06 | +22% | $42m | 0% |
How the EPS forecast has moved
The consensus EPS forecast for the current fiscal year is −16.0% on 90 days ago. In the last 30 days, 6 analysts raised Larimar Therapeutics, Inc.'s forecast and 0 cut it.
Average of analysts' published estimates (third-party data).
View chart data
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$1.61 | −$1.16 |
| 60 days ago | −$1.61 | −$1.18 |
| 30 days ago | −$1.35 | −$1.06 |
| 7 days ago | −$1.35 | −$1.06 |
| Now | −$1.35 | −$1.06 |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.38 | −$0.30 | +20.2% |
| Mar 2026 | −$0.59 | −$0.31 | +47.9% |
| Dec 2025 | −$0.55 | −$0.73 | −33.8% |
| Sept 2025 | −$0.42 | −$0.61 | −44.2% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 21.8% of tradable shares
- Days to cover
- 8.72 at average volume
- Short interest, 1 month
- +6% to October 15, 2026
- Held by institutions
- 94% of shares
- Held by insiders
- 1.2% of shares
- Employees
- 71 full time
Share-price performance
Market data may be delayedReturn and risk by year
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| LRMR | −50% | −62% | +10% | −15% | −2% | −38% |
| Industry peers (median) | −35% | −56% | −18% | −29% | −5% | −26% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| LRMR | 50% | 33% | 58% | 42% | 50% | 18% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| LRMR | −64% | −86% | −65% | −72% | −59% | −67% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since November 2, 2015: 99% from November 27, 2015 to August 5, 2022. Getting back needed a 13775% gain, and the shares have not yet recovered.
Price behaviour
- 52-week range
- $1.99 – $5.95
- From 52-week high
- −60.2%
- vs 50-day average
- −25.4%
- vs 200-day average
- −37.7%
- Volatility (1 year)
- 100%
- Beta vs S&P 500
- 1.64
Share price after results
- Next day
- 5 up, 7 down typical move ±7.1%
- After a week
- 4 up, 8 down typical move ±7.5%
- After a month
- 6 up, 6 down typical move ±8.8%
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 4, 2026 | +3.0% | +1.6% | +8.3% | −2.8% |
| May 14, 2026 | −12.7% | −0.4% | −12.9% | −12.4% |
| March 19, 2026 | +4.4% | −1.7% | +12.8% | +11.9% |
| January 12, 2026 | 0.0% | 0.0% | −3.9% | +0.3% |
| November 5, 2025 | −8.7% | −0.7% | −11.3% | −2.6% |
| August 14, 2025 | +7.8% | −0.2% | −0.8% | +6.5% |
| July 29, 2025 | −1.9% | −0.4% | +2.7% | +7.1% |
| April 30, 2025 | +19.7% | +0.7% | −9.2% | −5.9% |
| March 24, 2025 | −9.1% | +2.0% | −15.4% | −11.0% |
| October 30, 2024 | +5.7% | −2.3% | +4.9% | −18.6% |
| August 7, 2024 | −2.7% | +1.6% | −1.0% | +5.2% |
| May 9, 2024 | −10.1% | +0.7% | −6.2% | +21.5% |
Fundamentals
Who owns it
Funds buying and selling- Reported value
- $291M
- Institutions reporting
- 162
- Shares held vs prior quarter
- ▲ 8.8%
- Positions opened / closed
- 32 / 29
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Deerfield Management Company, L.P. | $109M | 35.6M | 37.3% | 0.0% |
| Blue Owl Capital Holdings LP | $27.9M | 9.2M | 9.6% | ▲ 28.7% |
| Blackrock, Inc. | $17.3M | 5.7M | 5.9% | ▲ 51.3% |
| Defilade Capital Management, L.P. | $11.2M | 3.7M | 3.8% | New |
| Driehaus Capital Management LLC | $9.6M | 3.2M | 3.3% | ▲ 7.8% |
| Vanguard Capital Management LLC | $9.1M | 3.0M | 3.1% | ▲ 3.8% |
| RTW Investments, LP | $7.8M | 2.6M | 2.7% | ▲ 71.1% |
| AQR Capital Management LLC | $7.2M | 2.4M | 2.5% | ▲ 190.1% |
| Marshall Wace, LLP | $6.1M | 2.0M | 2.1% | ▲ 115.6% |
| Dafna Capital Management LLC | $6.1M | 2.0M | 2.1% | ▼ 1.0% |
| Goldman Sachs Group Inc | $5.3M | 1.8M | 1.8% | ▲ 12.3% |
| Geode Capital Management, LLC | $5.1M | 1.7M | 1.8% | ▲ 51.4% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Larimar Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.
Insider trading activity
Full insider history and chart Insider purchases History → $25.7M 8 trades by 4 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $25.7M net buying
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Hamilton Thomas Edward Director | July 6, 2026 | Buy | 50,000 | $3.34 | $167,000 |
| Sherman Jeffrey W Director | February 27, 2026 | Buy | 5,000 | $5.00 | $25,000 |
| Thomas Frank E Director | February 27, 2026 | Buy | 5,000 | $5.00 | $25,000 |
| Hamilton Thomas Edward Director | February 27, 2026 | Buy | 100,000 | $5.00 | $500,000 |
| Deerfield Mgmt Hif, L.P. Director | February 27, 2026 | Buy | 1,084,012 | $5.00 | $5.4M |
| Deerfield Mgmt Hif, L.P. Director | February 27, 2026 | Buy | 831,978 | $5.00 | $4.2M |
| Deerfield Mgmt Hif, L.P. Director | February 27, 2026 | Buy | 2,000,000 | $5.00 | $10M |
| Deerfield Mgmt Hif, L.P. Director | February 27, 2026 | Buy | 1,084,010 | $5.00 | $5.4M |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
- August 4, 2026
- May 14, 2026
- March 19, 2026
- January 12, 2026
- November 5, 2025
- August 14, 2025
Recent SEC filings
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- DEF 14A Proxy statement
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Larimar Therapeutics, Inc. in brief
- What does Larimar Therapeutics, Inc. do?
- Larimar Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Larimar Therapeutics, Inc.'s stock ticker?
- Larimar Therapeutics, Inc. trades under the ticker LRMR on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Larimar Therapeutics, Inc.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Deerfield Management Company, L.P., Blue Owl Capital Holdings LP and Blackrock, Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- Are insiders buying or selling Larimar Therapeutics, Inc. stock?
- Over the last 12 months, Larimar Therapeutics, Inc.'s directors and officers reported 8 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
- When is Larimar Therapeutics, Inc.'s next earnings date?
- Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Larimar Therapeutics, Inc. announces its own schedule.
Follow research on Larimar Therapeutics, Inc.
New research on the companies we cover arrives in the weekly email. Free, one email a week.